Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 2 g ceftazidime [equivalent to 2.635 grams of ceftazidime pentahydrate/sodium carbonate powder] and 0.5 g avibactam [equivalent to 0.551 grams of avibactam sodium]) |
| Drug Class | Cephalosporin antibacterials and beta lactamase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of complicated intra-abdominal infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (at least 31 weeks gestational age), caused by designated susceptible Gram-negative microorganisms
- Indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adult and pediatric patients (at least 31 weeks gestational age), caused by designated susceptible Gram-negative microorganisms
- Indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), in adult and pediatric patients (at least 31 weeks gestational age), caused by designated susceptible Gram-negative microorganisms.
Latest News
Summary
- This summary is based on the review of 18 systematic review(s)/meta-analysis(es). [1-18]
- Mortality and Clinical Cure Rates in Nosocomial Infections: Ceftazidime/avibactam demonstrated lower mortality rates (odds ratio (OR) 2.73, 95% confidence interval (CI) 1.59-4.69) and higher clinical cure rates compared to polymyxin B in patients with multidrug-resistant infections, including carbapenem-resistant Enterobacterales (CRE).
- Efficacy in Nosocomial Pneumonia: Ceftazidime/avibactam showed a lower clinical failure rate than ceftazidime alone (OR = 1.48, 95% CrI [1.02-2.20]), though no significant difference in 28-day mortality was observed among beta-lactam regimens.
- Effectiveness in Complicated Intra-Abdominal Infections (cIAI): While ceftazidime/avibactam combined with metronidazole had higher adverse event-related discontinuations compared to meropenem, eravacycline showed improved microbiological response rates over tigecycline in cIAI.
- CRE and Multidrug-Resistant Infections: Ceftazidime/avibactam demonstrated lower mortality and higher clinical cure rates compared to colistin-based therapies in CRE infections, with synergistic effects noted when combined with agents such as aztreonam and amikacin.
- Adverse Events and Discontinuations: Ceftazidime/avibactam, when combined with metronidazole, showed higher discontinuation rates due to adverse events compared to meropenem in complicated intra-abdominal infections (cIAI).
- Nephrotoxicity: Ceftazidime/avibactam demonstrated lower nephrotoxicity rates than colistin-based regimens and polymyxin B, indicating a favorable nephrotoxicity profile compared to these alternatives in treating CRE and multidrug-resistant infections.
- Resistance Development: Emergence of resistance to ceftazidime/avibactam was observed, particularly in Klebsiella pneumoniae carbapenemase (KPC)-producing strains, suggesting a notable risk in prolonged or specific clinical contexts.
- Ceftazidime/avibactam demonstrated reduced mortality and higher clinical cure rates in the general population with nosocomial infections, showed favorable efficacy and safety profiles in newborns and pediatric patients with multidrug-resistant infections, and was effective in treating CRE infections with a lower nephrotoxicity risk compared to colistin-based regimens.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Avycaz (ceftazidime and avibactam) Prescribing Information. | 2024 | AbbVie Inc., North Chicago, IL |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant gram-negative bacteria | 2023 | Enfermedades Infecciosas y Microbiologia Clinica (English ed.) |
| Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) | 2022 | Infectious Diseases Society of America |